SCHEMBL14938112

SCHEMBL14938112

Cn1nccc1CCOc1ccc(C(F)(F)F)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOS1 P29475 4/20 0.50
AR P10275 2/20 0.48
KCNH2 Q12809 1/20 0.48
HDAC1 Q13547 1/20 0.48
HDAC8 Q9BY41 1/20 0.48
HDAC6 Q9UBN7 1/20 0.48
LTA4H P09960 1/20 0.45
CYP1A2 P05177 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2D6 P10635 1/20 0.43
CYP19A1 P11511 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
DRD2 P14416 4/20 0.43
DRD1 P21728 1/20 0.43
DRD3 P35462 1/20 0.43
HMOX1 P09601 1/20 0.41
NSD2 O96028 1/20 0.41
NSD3 Q9BZ95 1/20 0.41
OXTR P30559 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17298797 0.82 CYP1A2 (0.48) ARKCNH2HDAC1HDAC8HDAC6
SCHEMBL14938123 0.79 TAAR1 (0.44) HDAC1HDAC8HDAC6HMOX1OXTR
SCHEMBL14937426 0.74 DAO (0.44) HDAC1HDAC8HDAC6CYP1A2OXTR
SCHEMBL14938133 0.74 NOS1 (0.44) NOS1LTA4HDRD2DRD1DRD3
SCHEMBL31425748 0.71 CYP1A2 (0.38) ARKCNH2HDAC1HDAC8HDAC6
SCHEMBL2265322 0.71 KCNH2 (0.53) ARKCNH2CYP1A2CYP3A4CYP2D6
SCHEMBL14937943 0.71 KDM4C (0.50) CYP3A4CYP2C19DRD3OXTRAVPR1A
SCHEMBL14938259 0.70 HDAC1 (0.49) HDAC1HDAC8HDAC6OXTRAVPR1A
SCHEMBL16774590 0.70 CYP1A2 (0.58) KCNH2LTA4HCYP1A2CYP3A4CYP2D6
SCHEMBL14938195 0.70 OXTR (0.41) NOS1KCNH2HDAC1HDAC8HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8642626-B2 Ethinyl-pyrazole derivative TAISHO PHARMACEUTICAL CO., LTD. (JP) 2014-02-04 US disclosed
EP-2604602-A1 HETEROARYL-PYRAZOLE DERIVATIVE Taisho Pharmaceutical Co., Ltd. (JP) 2013-06-19 EP disclosed
EP-2599775-A1 ETHINYL-PYRAZOLE DERIVATIVE Taisho Pharmaceutical Co., Ltd. (JP) 2013-06-05 EP disclosed
US-20130137865-A1 HETEROARYL-PYRAZOLE DERIVATIVE TAISHO PHARMACEUTICAL CO., LTD. (JP) 2013-05-30 US disclosed
US-20130123500-A1 ETHINYL-PYRAZOLE DERIVATIVE TAISHO PHARMACEUTICAL CO., LTD (JP) 2013-05-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130137865-A1 HETEROARYL-PYRAZOLE DERIVATIVE GRIN2C, GRIN2B, GRIN3A NOS1 3794/4885AR 2251/4885KCNH2 1221/4885
US-20130123500-A1 ETHINYL-PYRAZOLE DERIVATIVE GABRE, GRIN3A, GRIK5 NOS1 3678/4885AR 2655/4885KCNH2 1681/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.